Texas COVID-19 Therapeutics Provider Webinar

September 27, 2021
DISCLAIMER

The information presented today is based on current guidance and authorizations and MAY change.

September 27, 2021
Agenda Topics

- Opening Remarks – Jennifer Shuford, MD, MPH
- COVID-19 mAb Therapeutics – Saroj Rai, PhD, MPH
  - Federal & State Reporting Requirements
  - Resources
- *Live Q&A*
- Vaccine Allocation & Ordering System (VAOS)
- Shipping Timelines
- *Live Q&A*
Opening Remarks

Dr. Jennifer Shuford, MD, MPH
Chief State Epidemiologist | Office of the Chief State Epidemiologist
On September 13, 2021, US Department of Health and Human Services (US HHS) notified states that, due to supply constraints, providers may no longer order COVID-19 monoclonal antibody (mAb) therapeutics direct from AmerisourceBergen Corporation (ABC).

US HHS will provide weekly allocations to the states. The states will make allocations to their providers.

This is specific for the following COVID-19 mAb therapeutics only:
- **REGEN-COV™** (casirivimab/imdevimab; manufactured by Regeneron)
- **bamlanivimab/etesevimab** (manufactured by Eli Lilly).

Texas Department of State Health Services (DSHS) has worked to put a system in place for providers to make requests for COVID-19 mAb therapeutics.

**Sotrovimab** (GlaxoSmithKline) can be purchased through normal purchasing routes from the distributor
COVID-19 mAb Therapeutics Ordering
Vaccine Allocation and Ordering System (VAOS)

- Many Texas providers are already familiar with the Texas COVID-19 Vaccine Allocation and Ordering System (VAOS).
- DSHS has added a module in VAOS to allow providers to put in COVID-19 mAb therapeutics requests.
- Providers already registered in VAOS and are registered with ABC as a COVID-19 mAb therapeutics provider are able to make requests already.
- Providers already registered with ABC as a COVID-19 mAB therapeutics provider received access to VAOS last Friday.
  - Will go through a detailed training today on VAOS and ordering.
- Providers who do not have an mAb account with ABC must get one before being able to place orders.
Federal Allocation of COVID-19 mAb Therapeutics

• US HHS has indicated that allocations to the states will decline in coming weeks due to supply limitations.

• DSHS understanding is that allocations to the state will be determined by the following factors:
  • State population
  • State COVID-19 cases and hospitalizations
  • Provider adherence to reporting requirements
    • Weekly Federal reporting to TeleTracking
    • Daily State reporting
      • TDEM Portal and
      • ImmTrac2

• The federal government has indicated that utilization and reporting will impact future Texas allocations.
DSHS is working to implement a fair allocation strategy that ensures Texas is well positioned to receive its maximum allocation each week.

DSHS will consider the following factors when evaluating provider requests:

- Provider use and reporting
- Geographic coverage
- Rural and urban coverage
- Proportionality to eligible population estimates

Provider reporting will be a key and a deciding factor for whether a provider may receive mAb allocations.
Weekly Allocation Summary

• Available weekly COVID-19 mAb therapeutics for allocations

<table>
<thead>
<tr>
<th></th>
<th>Week 1 (Week of Sept 13th)</th>
<th>Week 2 (Week of Sept 20th)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAN + ETE</td>
<td>2,370 Patient Courses</td>
<td>6,144 Patient Courses</td>
</tr>
<tr>
<td>REGEN-COV</td>
<td>21,270 Patient Courses</td>
<td>14,316 Patient Courses</td>
</tr>
</tbody>
</table>

• Due to the high demand and limited supply of COVID-19 mAb therapeutics, not all requests will be fulfilled at this time.

• Providers that do not report will not receive allocations.
COVID-19 Monoclonal Antibody (mAb) Therapeutics

Saroj Rai, PhD, MPH
Senior Scientific Advisor | Office of the Chief State Epidemiologist
### FDA Emergency Use Authorized COVID-19 Monoclonal Antibody Therapeutics Available Through State Ordering

<table>
<thead>
<tr>
<th>Monoclonal Antibody</th>
<th>Indications and Routes of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>bamlanivimab and etesevimab</strong>&lt;sup&gt;1&lt;/sup&gt;&lt;br&gt;(Eli Lilly)&lt;sup&gt;***&lt;/sup&gt;</td>
<td><strong>TREATMENT</strong> of Mild to Moderate COVID-19 Infection within 10 days of symptom onset in patient with high risk of progression to severe disease**&lt;br&gt;Dose: 700 mg bamlanivimab and 1400 mg etesevimab**&lt;sup&gt;***&lt;/sup&gt;&lt;br&gt;<strong>Route: Intravenous administration</strong>&lt;br&gt;Post-administration monitoring: 60 minutes</td>
</tr>
</tbody>
</table>

| **casirivimab and imdevimab**<sup>2</sup><br>(REGEN-COV) | **TREATMENT** of Mild to Moderate COVID-19 Infection within 10 days of symptom onset in patient with high risk of progression to severe disease**<br>Dose: casirivimab 600mg and imdevimab 600mg<br>**Route: Intravenous is preferred route, however subcutaneous injection may be utilized in situations where there would be a delay in intravenous administration**<br>Post-administration monitoring: 60 minutes | **POST-EXPOSURE PROPHYLAXIS** for individuals who are not fully vaccinated or immunocompromised, with high risk of progression to severe disease**<br>Dose: casirivimab 600mg and imdevimab 600mg<br>**Route: Intravenous or subcutaneous**<br>Post-administration monitoring: 60 minutes |

---

*** Based on the most currently available data, bamlanivimab and etesevimab are now authorized in all U.S. states, territories, and jurisdictions (9/2/21) [https://www.fda.gov/media/151719/download]

Refer to product Emergency Use Authorizations for detail on indications and administration

1 Fact Sheet for Health Care Providers Emergency Use Authorization of Bamlanivimab and Etesevimab [https://www.fda.gov/media/145802/download]

2 Fact Sheet for Health Care Providers Emergency Use Authorization of REGEN-COV™ (casirivimab and imdevimab) [https://www.fda.gov/media/145611/download]

Patient Eligibility

Bamlanivimab and Etesevimab (BAM/ETE) & Casirivimab and Imdevimab (REGEN-COV)

- For the **treatment** mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk* for progression to severe COVID-19, including hospitalization or death.

- **Not authorized** for use in patients:
  - who are hospitalized due to COVID-19, OR
  - who require oxygen therapy due to COVID-19, OR
  - who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

- Adult and pediatric individuals (12 years of age and older weighing at least 40 kg) for **post-exposure prophylaxis** of COVID-19 in individuals who are at high risk* for progression to severe COVID-19, including hospitalization or death, and are:
  - not fully vaccinated or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications2) and
    - have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Center for Disease Control and Prevention (CDC)3 or
    - who are at high risk of exposure to an individual infected with SARS-CoV-2
  - not a substitute for vaccination against COVID-19
  - not authorized for pre-exposure prophylaxis

**REGEN-COV™ (casirivimab and imdevimab)**

- Current authorized dose is **600 mg casirivimab and 600 mg imdevimab** for treatment and post-exposure prophylaxis.
  - Note: this is a change from the previous dose of **1,200 mg casirivimab and 1,200 mg imdevimab**.
- Due to multiple presentations, it is important to know the different presentations and how to prepare doses appropriately with each presentation ([Medication Error](#)).
- REGEN-COV is authorized for intravenous infusion. Subcutaneous injection is authorized as an alternative route of administration when intravenous infusion is not feasible and would lead to delay in treatment.
- For post-exposure prophylaxis, either subcutaneous injection or intravenous infusion can be used.
- Lower dosage for repeat dosing post-exposure prophylaxis for ongoing exposure in settings like nursing homes and jails. Refer to the [Fact Sheet](#).

---

**bamlanivimab and etesevimab (Eli Lilly)**

- Current authorized dose is **700 mg bamlanivimab and 1,400 mg etesevimab** for treatment and post-exposure prophylaxis.
- Must be administered together after dilution by intravenous (IV) infusion only.

---

Fact Sheet for Health Care Providers Emergency Use Authorization of Bamlanivimab and Etesevimab ([https://www.fda.gov/media/145802/download](https://www.fda.gov/media/145802/download))
Fact Sheet for Health Care Providers Emergency Use Authorization of REGEN-COV™ (casirivimab and imdevimab) ([https://www.fda.gov/media/145611/download](https://www.fda.gov/media/145611/download))
The COVID-19 Treatment Guidelines Panel recommends using anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild to moderate COVID-19 and for post-exposure prophylaxis (PEP) of SARS-CoV-2 infection in individuals who are at high risk for progression to severe COVID-19, as outlined in the FDA Emergency Use Authorizations (EUAs). See the individual EUAs for details.

Logistical constraints (e.g., limited space, not enough staff who can administer therapy) can make it difficult to administer these agents to all eligible patients. In situations where it is necessary to triage eligible patients, the Panel suggests:

- Prioritizing the treatment of COVID-19 over PEP of SARS-CoV-2 infection.
- Prioritizing the following groups over vaccinated individuals who are expected to have mounted an adequate immune response:
  - Unvaccinated or incompletely vaccinated individuals who are at high risk of progressing to severe COVID-19.
  - Vaccinated individuals who are not expected to mount an adequate immune response (e.g., immunocompromised individuals).

Providers should use their clinical judgment when prioritizing treatment or PEP in a specific situation. When there are no logistical constraints for administering therapy, these considerations should not limit the provision of anti-SARS-CoV-2 monoclonal antibodies.
### Summary

<table>
<thead>
<tr>
<th></th>
<th>FDA Authorized</th>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Treatment</td>
<td>Post-Exposure Prophylaxis</td>
</tr>
<tr>
<td><strong>REGEN-COV</strong> (600 mg cas + 600 mg imd)</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td><strong>BAM/ETE</strong> (700 mg bam + 1,400 mg ete)</td>
<td>YES</td>
<td>YES</td>
</tr>
</tbody>
</table>
### COVID-19 mAb Therapeutics

#### Storage and Handling

**casirivimab and imdevimab (REGEN-COV™)**

- Store unopened casirivimab and imdevimab vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
- **DO NOT FREEZE, SHAKE, OR EXPOSE TO DIRECT LIGHT.**
- Solution in vial requires dilution prior to intravenous administration.
- The prepared infusion solution is intended to be used immediately.
  - If immediate administration is not possible, store diluted casirivimab and imdevimab infusion solution:
    - In the refrigerator at 2°C to 8°C (36°F to 46°F) for no more than **36 hours** or
    - At room temperature up to 25°C (77°F) for no more than **4 hours**
    - If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 30 minutes prior to administration
- The prepared syringes should be administered immediately.
  - If immediate administration is not possible, store the prepared casirivimab and imdevimab syringes:
    - In the refrigerator at 2°C to 8°C (36°F to 46°F) for no more than **4 hours** or
    - At room temperature up to 25°C (77°F) for no more than **4 total hours**
    - If refrigerated, allow the syringes to equilibrate to room temperature for approximately 20 minutes prior to administration

**bamlanivimab and etesevimab (Eli Lilly)**

- Store unopened vials under refrigerated temperatures at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
- **DO NOT FREEZE, SHAKE, OR EXPOSE TO DIRECT LIGHT.**
- Solution in vial requires dilution prior to administration.
- The prepared infusion solution is intended to be used immediately.
  - If immediate administration is not possible, store diluted infusion solution:
    - In the refrigerator at 2°C to 8°C (36°F to 46°F) for up to **24 hours** or
    - At room temperature (20°C to 25°C [68°F to 77°F]) for up to **7 hours**, **including infusion time**
    - If refrigerated, allow the infusion solution to equilibrate to room temperature prior to administration
COVID-19 mAb Therapeutics

Federal & State Reporting Requirements
State Reporting Requirements

• Administration of all COVID-19 monoclonal antibody therapeutics must be reported daily to:
  1. Texas Division of Emergency Management (TDEM) Portal
  2. ImmTrac2

• Adherence to the Texas reporting requirements is critical and will impact future allocations.
State Reporting Requirements - TDEM

• Administration of all COVID-19 monoclonal antibody therapeutics must be reported daily to Texas Division of Emergency Management (TDEM) Portal.
  
  To register for TDEM:
  • Go to [https://report.tedem.Texas.gov](https://report.tedem.Texas.gov)
  • Select “Facility Not Listed? Request To Add It

• Adherence to the Texas reporting requirements is critical and will impact future allocations.
State Reporting Requirements – ImmTrac2

- Administration of all COVID-19 monoclonal antibody therapeutics must be reported daily to ImmTrac2.
- Register for ImmTrac 2 if your organization has never accessed ImmTrac before: https://immtrac.dshs.texas.gov/TXPRD/enrollProviderEntry.do?action=newOrg
- Adherence to the Texas reporting requirements is critical and will impact future allocations.

https://www.dshs.texas.gov/immunize/immtrac/docs/11-15065.pdf
Federal Reporting Requirement

- Administration of all COVID-19 monoclonal antibody therapeutics must be reported weekly on Wednesdays to HHS TeleTracking.

  HHS TeleTracking: https://teletracking.protect.hhs.gov/

- Hospitals that are required to report daily data to HHS per the CMS CoP do not need to report directly in TeleTracking.

- Adherence to the Federal reporting requirements is critical and will impact all future Texas allocations.
# Required Reporting Summary

<table>
<thead>
<tr>
<th>All Provider Types</th>
<th>ImmTrac2 (State) Daily</th>
<th>TDEM Portal (State) Daily</th>
<th>TeleTracking Federal Weekly (Wednesday)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>All</td>
<td>All</td>
<td>All facilities that are NOT required to report daily data to HHS per the CMS CoP.</td>
</tr>
</tbody>
</table>

*Adherence to all reporting requirements is critical and will impact all future Texas allocations.*
Resources
Provider and Patient EUA Fact Sheets

• Each product under EUA also has an FDA fact sheet for providers and one for patients and caregivers.

• **bamlanivimab and etesevimab**
  - Provider fact sheet: [https://www.fda.gov/media/145802/download](https://www.fda.gov/media/145802/download)
  - Patient fact sheet: [https://www.fda.gov/media/145803/download](https://www.fda.gov/media/145803/download)

• **casirivimab and imdevimab (REGEN-COV)**
  - Provider fact sheet: [https://www.fda.gov/media/145611/download](https://www.fda.gov/media/145611/download)
  - Patient fact sheet: [https://www.fda.gov/media/145612/download](https://www.fda.gov/media/145612/download)

Provider Mandatory Reporting

Medication Errors & Serious Adverse Events

**REGEN-COV™**
(casirivimab and imdevimab)

- Submit adverse event reports to FDA MedWatch using one of the following methods:
  - Complete and submit the report online: [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm), or
  - Complete and submit a postage-paid FDA Form 3500 ([https://www.fda.gov/media/76299/download](https://www.fda.gov/media/76299/download)) and return by:
    - Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
    - Fax (1-800-FDA-0178), or
    - Call 1-800-FDA-1088 to request a reporting form.
- In addition, please provide a copy of all FDA MedWatch forms to:
  Regeneron Pharmaceuticals, Inc
  Fax: 1-888-876-2736
  E-mail: medical.information@regeneron.com
  Or call Regeneron Pharmaceuticals at 1-844-734-6643

**bamlanivimab and etesevimab**
(Eli Lilly)

- Submit adverse event reports to FDA MedWatch using one of the following methods:
  - Complete and submit the report online: [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm), or
  - Complete and submit a postage-paid FDA Form 3500 ([https://www.fda.gov/media/76299/download](https://www.fda.gov/media/76299/download)) and return by:
    - Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
    - Fax (1-800-FDA-0178), or
    - Call 1-800-FDA-1088 to request a reporting form.
- In addition, please provide a copy of all FDA MedWatch forms to:
  Eli Lilly and Company, Global Patient Safety
  Fax: 1-317-277-0853
  E-mail: mailindata.gmsmtindy@lilly.com
  Or call Eli Lilly and Company at 1-855-LillyC19 (1-855-545-5921)
Manufacturers’ Contact Information

Regeneron Medical Information Contact
1-800-743-6643
www.REGENCOV.com

Eli Lilly Medical Information Contact
1-800-545-5921
www.LillyAntibody.com
For questions about ordering therapeutics:

Email therapeutics@dshs.texas.gov

Call the Provider Support Center at 833-832-7068 and press 0 to speak to a representative about ordering therapeutics
Office Call Sessions on Distribution and Administration of COVID-19 Therapeutics

- This session is an open forum for state and territorial health officers, health care providers and professionals at administration sites to ask HHS/ASPR your questions on administration of therapies.
- Tuesdays and Thursdays (1:00 – 2:00PM CT)

Email therapeutics@dshs.Texas.gov for meeting link.
## Helpful Links

<table>
<thead>
<tr>
<th>Category</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal Monoclonal Antibody Site</td>
<td><a href="https://www.phe.gov/mAbs">https://www.phe.gov/mAbs</a></td>
</tr>
<tr>
<td>PHE COVID-19 Toolkit</td>
<td><a href="https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/toolkit.aspx">https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/toolkit.aspx</a></td>
</tr>
<tr>
<td>Regeneron Clinical Trials</td>
<td><a href="https://www.regeneron.com/covid19">https://www.regeneron.com/covid19</a></td>
</tr>
</tbody>
</table>
## Helpful Resources for Clinicians

<table>
<thead>
<tr>
<th>Resource</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMS Template Protocol</td>
<td><a href="https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/EMS-Template-Protocol-for-COVID19-mAbs-Administration.aspx">https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/EMS-Template-Protocol-for-COVID19-mAbs-Administration.aspx</a></td>
</tr>
<tr>
<td>Guides on Vaccination after mAb administration</td>
<td><a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html</a></td>
</tr>
</tbody>
</table>
Live Q&A
Welcome to Vaccine Allocation & Ordering System (VAOS)
Adding Therapeutics Providers to VAOS

Access email was sent this morning

This weekend, all therapeutics providers with ABC (AmerisourceBergen) accounts but without VAOS accounts were added to VAOS (Vaccine Allocation & Ordering System).

This morning, an email was sent out with access instructions for these providers. Please follow the instructions in this email from IdentityManagement@hhsc.state.tx.us. If you cannot find this email, contact therapeutics@dshs.texas.gov.
New to VAOS?

What is VAOS?
The Vaccine Allocation and Ordering System (VAOS) is a platform built for the distribution and management of the COVID-19 vaccines, COVID-19 therapeutics products, and other vaccines.

There are two key requirements for providers who’d like to place a therapeutics order:

- Have an AmerisourceBergen account
- Be enrolled in VAOS

For more information on utilizing VAOS and placing a therapeutics request, you can review the following job aid:
Rules of the Road!

*Remember...*

Only the **primary and backup coordinators** will get access to VAOS. The Department of State Health Services (DSHS) will create your VAOS account. Two users per facility will have full access to VAOS. VAOS access can be requested for two users to be added as Therapeutics Coordinators, who will only be able to request COVID-19 therapeutics (and won’t have access to inventory management or vaccine requests).

You can start placing COVID-19 therapeutics requests **as soon as you receive VAOS access**. You will only be able to place requests for order types you have been given access to (e.g., therapeutics providers can request therapeutics but not vaccines).

If you have questions related to therapeutics, contact the Provider Help Desk: 833-832-7068, option 0 8 a.m. to 5 p.m., Monday through Friday or email [therapeutics@dshs.Texas.gov](mailto:therapeutics@dshs.Texas.gov).
1. Register with Amerisource Bergen
   Email Therapeutics@dshs.Texas.gov to start the process to set up an account.

2. Gain Access to VAOS
   DSHS will create your account. You cannot create a VAOS account yourself.

3. Watch for an email with login credentials
   Providers will receive:
   - An email from IdentityManagement@hhsc.state.tx.us with log in credentials
   - An email from COVID19VacMgmt@dshs.Texas.gov with instructions to log into VAOS.
Accessing Your VAOS Account

Please contact therapeutics@dshs.Texas.gov with any sign on issues

1. Vaccine Coordinators and/or Therapeutics Coordinators will receive an encrypted email from IdentityManagement@hhsc.state.tx.us

2. The email will need to be decrypted. To decrypt the email, select the message file and choose to open it.

3. You will be redirected to a web browser. From here, select Use a one-time passcode.

4. Your temporary code will be emailed to you.

5. Enter your one-time code and select Continue.
Accessing Your VAOS Account

6. Once you select **Continue** the encrypted message will open.

7. The message will contain **your username and a temporary password** for VAOS.

8. Select the link to VAOS to be redirected to the VAOS login page.
9. Use the provided **credentials** from the **encrypted email** to log in and **change the temporary password** to a password of your choosing. You will be prompted to do this.
Navigating VAOS
After logging in, you’ll reach the home page.

Note! Depending on your login access and system updates, your home page might look different than the example to the right.
VAOS Home Page Modules

Therapeutic coordinators will utilize **three modules within VAOS**. You can select each of the modules on your home page to view different information or perform different tasks.

- **The Account module** is where you can upload your monthly temperature log.
- **The “Transfers and COVID-19 Vaccine Requests” module** is where you can order therapeutics, view past orders, and place transfer requests.
- **The Updates and Resources module** is where you will find resources for navigating VAOS, an outline of the most recent system updates, and contact information.
Step-by-Step VAOS Instructions

Review the COVID-19 Therapeutics Ordering Request job aid for step-by-step instructions on placing a COVID-19 therapeutic order in VAOS.  
Live Demo – Navigating VAOS
Welcome to
Texas Vaccine Allocation & Ordering System
One-stop solution for all vaccine allocation and ordering needs for the Department of State Health Services, Immunization Unit

Updates and Reminders

Accounts
Enter TVFCASH/Yu Doses Adminis...
Enter Vaccine Loss
Open Ordering (TVFCASH/Yu)
COVID Dashboard
Transfer & COVID Vaccine Requests
Reports
Updates and Resources
COVID-19 mAb Therapeutics
Ordering through VAOS
Providers can request COVID-19 mAb Therapeutics by patient course:

- **REGEN-COV™** *(casirivimab/imdevimab; manufactured by Regeneron)*
  - Must be ordered in multiples of **12 patient courses**
- **Bam/Ete** *(bamlanivimab/etesevimab; manufactured by Eli Lilly)*
  - Must be ordered in multiples of **10 patient courses**
Order Request Checklist

Before you begin...

Ensure You Have the Following:

- Number of courses and type of course you plan to request
- Your AmerisourceBergen account number
- Current quantity of patient course you have on hand
- Method of Administration and Use for the therapeutics
- Primary and Secondary contact information and AmerisourceBergen shipping address

You will need an AmerisourceBergen account to order any therapeutics through VAOS. You can contact therapeutics@dshs.Texas.gov to learn more about creating an account.
Ordering Module

From the homepage, select “Transfers & COVID Vaccine Requests” tab.
Create New COVID Therapeutics Order Request

1. From the service request form select **New**.

2. From the **New Service Request** pop up box. Select **COVID Therapeutics Order Request**.

3. Select **Next**.
Enter Ordering Information

Fill out all required fields in the “New Service Request” form.

<table>
<thead>
<tr>
<th>Field Title</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current quantity</td>
<td>Enter the number of courses you currently have on hand</td>
</tr>
<tr>
<td>Courses requested</td>
<td>Enter the number of courses you would like to order</td>
</tr>
<tr>
<td>AmerisourceBergen Account Number</td>
<td>Input your AmerisourceBergen account information (It’s required to order therapeutics)</td>
</tr>
<tr>
<td>Intended Method of Admin</td>
<td>Choose your method of administration</td>
</tr>
<tr>
<td>Intended use of the therapeutics product</td>
<td>Choose the intended use of the product</td>
</tr>
<tr>
<td>Contact Information</td>
<td>Fill out primary and secondary contact information</td>
</tr>
<tr>
<td>AmerisourceBergen Shipping Address</td>
<td>Input the shipping address that is in your AmerisourceBergen account</td>
</tr>
</tbody>
</table>
Live Demo – Placing a Therapeutics order in VAOS
Therapeutic Order Form

Important Notes

1. The shipping address you list in the therapeutic order request form **MUST** be the same as your AmerisourceBergen shipping address.

2. Don’t forget to check the “willing to accept another product” box, if you are willing to accept either product in the event your original choice is unavailable.

3. Remember! **REGEN-COV** must be ordered in multiples of 12 patient courses and **Bam/Ete** must be ordered in multiples of 10 patient courses.
Currently, there will be no inventory management for therapeutics in VAOS.

What does that mean?

• *NO* reporting waste features in VAOS for therapeutics
• You *CANNOT* view shipment and inventory records for therapeutics
Review a Service Request
From the home page, select **Vaccine Requests and Transfers**.
1. Open the dropdown menu
2. Select “Therapeutics Order Requests”
From the Service Request screen, you can view your past orders. Select the order you’d like to view or edit.

<table>
<thead>
<tr>
<th></th>
<th>Service Request No.</th>
<th>Facility</th>
<th>Patient Course...</th>
<th>Patient Course...</th>
<th>Willing to acc...</th>
<th>Status</th>
<th>Created Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SR-62426</td>
<td>Texas Test</td>
<td>0</td>
<td>10</td>
<td></td>
<td>Created</td>
<td>9/16/2021, 9:24 PM</td>
</tr>
<tr>
<td>2</td>
<td>SR-62427</td>
<td>Texas Test</td>
<td>4</td>
<td>10</td>
<td></td>
<td>Created</td>
<td>9/16/2021, 9:26 PM</td>
</tr>
<tr>
<td>3</td>
<td>SR-62428</td>
<td>Texas Test</td>
<td>10</td>
<td>0</td>
<td></td>
<td>Created</td>
<td>9/17/2021, 8:06 AM</td>
</tr>
<tr>
<td>4</td>
<td>SR-62429</td>
<td>Texas Test</td>
<td>0</td>
<td>10</td>
<td></td>
<td>Created</td>
<td>9/17/2021, 8:14 AM</td>
</tr>
</tbody>
</table>
Viewing Order Status

Once your status is classified as “Exported” in VAOS, you will *not* be able to modify, cancel, or return the order.
Live Demo – View a Service Request
Shipping Timelines
Shipment Notification Email

Providers will receive an email regarding their therapeutics shipment from AmerisourceBergen c19therapies@amerisourcebergen.com.

At this time, VAOS will not reflect any approval or shipment information regarding therapeutics allocation requests or orders.
Therapeutic Ordering Timeline

Providers may enter requests at any time

Mondays
Providers must place orders by 10:00 am Monday each week.

**HHS will announce state distribution amounts every Monday**

Wednesdays
Weekly HHS Teletracking must be done by then. US HHS will take its snapshot of provider mAb use, which will feed into Texas’s future allocations from HHS.

Fridays
The state must enter all orders for the state by end of day.

Following Week
Allocation shipments will be received.

- **Remember!** Shipments will arrive throughout the week. Shipments will only arrive on weekdays.
Weekly Allocation Cadence

• Providers need to place requests by 10:00 am CST Monday.
• DSHS receives allocations every Monday.
• Providers could receive orders the same week or the following week.
• Providers will receive shipments on weekdays only.
Live Q&A
Final Notes
Have Questions or Need Help?

Contact COVID-19 Support at **833-832-7068, option “0”** from 8:00AM-5:00PM Monday –Friday.
Look for Our Follow-Up Email!

Monitor your inbox for a follow-up email communication that contains a link to access today’s webinar materials.

The email also contains helpful links and resources.

The follow-up email will come from GovDelivery.

This is where you can view today’s (and past) webinars, as well as Highlights and the slides we presented.
The information presented today is based on current authorization and guidance and MAY change.

September 27, 2021